Delivering Breakthrough Vaccines

IVT’s goal is to generate sustainable, long-term revenues by developing and commercializing VacciMax® based vaccines through early clinical development, multiple partnerships and licensing agreements with major vaccine companies.

	LATEST NEWS

	Vaccine Development Aided by New Techniques
	On The Move - ImmunoVaccine Technologis Inc. has been selected as one of Canada's Top 10 Life Sciences Companies
	Vaccine breakthrough heralds new cancer treatment
	ImmunoVaccine Technologies’ DepoVax™ Shows Positive Results for Cancer and Infectious Diseases
	ImmunoVaccine Technologies selected as Canada's Top 10™ Life Sciences Companies

COMPANY PROFILE

ImmunoVaccine Technologies Inc. (IVT) is a clinical stage private biotechnology company developing therapeutic cancer and prophylactic infectious disease vaccines for human health. IVT is commercializing breakthrough vaccines developed through the combination of the VacciMax® platform, a vaccine delivery and enhancement system and a large selection of validated vaccine antigens. The combination of the right antigens and strong novel delivery will give IVT’s pipeline a distinct competitive advantage and will position IVT as a key player in development of premium vaccine products.

The VacciMax® platform is able to stimulate an earlier, more powerful, long lasting antibody and cellular immune response. IVT is also able to reduce the number of doses required for protection against infectious diseases like influenza. IVT has completed the scale-up and manufacturing method development for the VacciMax® platform. The company is conducting a Phase 1 clinical trial of IMT 1012, a therapeutic breast and ovarian cancer vaccine and is planning to begin a second Phase 1 for a therapeutic prostate cancer vaccine in early 2009.

For more information, please go to our Document Library www.deliveringbreakthroughs.com